Macro Capital suffered 86.02%% year-on-year (YoY) lower consolidated net losses attributable to the parent company at EGP 38.098 million in 2024
Updated 2/26/2025 3:02:00 AM
Macro Group Pharmaceutical (Macro Capital) has incurred a consolidated net loss attributable to the parent company worth EGP 66.119 million during the first nine months of 2024, versus net profits amounting to EGP 98.090 million in the same period a year earlier.
Updated 11/12/2024 9:51:00 AM
Macro Group Pharmaceutical (Macro Capital) recorded EGP 88.799 million in consolidated net losses attributable to the parent company during the first half (H1) of 2024, compared to EGP 29.338 million in net profits in H1 2023.
Updated 9/4/2024 11:12:00 AM
Macro Group Pharmaceutical (Macro Capital) recorded EGP 78.112 million in consolidated net losses attributable to the parent company during the first quarter (Q1) of 2024, compared to EGP 9.445 million in net profits in H1 2023.
Updated 7/30/2024 9:13:00 AM
Macro Group Pharmaceutical (Macro Capital) has incurred EGP 272.651 million in consolidated net losses attributable to the parent company during the first quarter (Q1) of 2024, versus net profits amounting to EGP 173.835 million during the first three months of 2023, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on April 16th.
Updated 4/16/2024 10:39:00 AM
Macro Group Pharmaceutical (Macro Capital) (MCRO) posted a 24.22% year-on-year (YoY) decrease in consolidated profit attributable to the parent company during the first nine months of 2023.
Updated 11/15/2023 2:03:00 AM
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
Updated 8/16/2023 9:22:00 AM
Macro Group Pharmaceutical (Macro Capital) has reported a 69.2% year-on-year (YoY) decline in consolidated profits attributable to the parent company during the first quarter (Q1) of 2023.
Updated 5/17/2023 10:33:00 AM
Macro Group Pharmaceutical (Macro Capital) announced that it is targeting sales of EGP 1 billion in 2023 via maintaining the 25-30% expected growth rate this year.
Updated 4/10/2023 11:41:00 AM
Macro Group Pharmaceuticals has approved the payment of EGP 0.1067 per share in cash dividends to shareholders for 2022 over two installments.
Updated 4/6/2023 11:37:00 AM
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
Updated 3/8/2023 11:26:00 AM
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
Updated 3/2/2023 10:39:00 AM